NCT02782663 is a Phase 2 clinical trial of ABT-494 in Crohn's Disease (CD), sponsored by AbbVie.

Who is sponsoring NCT02782663?

NCT02782663 is sponsored by AbbVie.

What drugs are being tested in NCT02782663?

Interventions in NCT02782663: ABT-494.

What condition does NCT02782663 study?

NCT02782663 studies Crohn's Disease (CD).

Is NCT02782663 still recruiting?

NCT02782663 is currently completed. Last updated 31 July 2025.

Last reviewed 2025-07-31 · How we verify

NCT02782663

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

Completed Phase 2 Last updated 31 July 2025

What this trial tests

Phase 2 trial testing ABT-494 in Crohn's Disease (CD) in 107 participants. Completed in 18 July 2025.

Timeline

18 May 2016

Primary endpoint
18 July 2025

18 July 2025

Quick facts

Lead sponsor	AbbVie
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	107
Start date	18 May 2016
Primary completion	18 July 2025
Estimated completion	18 July 2025
Sites	61 locations across Denmark, France, Italy, Netherlands, New Zealand, Slovakia, Belgium, United Kingdom

Drugs / interventions tested

ABT-494 — full drug profile →

Conditions studied

Crohn's Disease (CD) — all drugs for Crohn's Disease (CD) →

Sponsor

AbbVie — full company profile →

Who can join

Adults 18 to 75, any sex, with Crohn's Disease (CD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.
Schwartz DM, Kanno Y, Villarino A, Ward M, et al · · 2017 · cited 308× · PMID 29282366 · DOI 10.1038/nrd.2017.267
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
Fragoulis GE, McInnes IB, Siebert S. · · 2019 · cited 223× · PMID 30806709 · DOI 10.1093/rheumatology/key276
Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review).
Ahmad R, Singh JK, Wunnava A, Al-Obeed O, et al · · 2021 · cited 130× · PMID 33655327 · DOI 10.3892/ijmm.2021.4847
Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines.
Porter RJ, Arends MJ, Churchhouse AMD, Din S. · · 2021 · cited 103× · PMID 34111282 · DOI 10.1093/ecco-jcc/jjab102
Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease.
Na SY, Moon W. · · 2019 · cited 99× · PMID 31195433 · DOI 10.5009/gnl19019
JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.
Luo Y, Alexander M, Gadina M, O'Shea JJ, et al · · 2021 · cited 92× · PMID 34625141 · DOI 10.1016/j.jaci.2021.08.004
The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.
Schroeder MA, Choi J, Staser K, DiPersio JF. · · 2018 · cited 82× · PMID 29289756 · DOI 10.1016/j.bbmt.2017.12.797
The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
De Vries LCS, Wildenberg ME, De Jonge WJ, D'Haens GR. · · 2017 · cited 82× · PMID 28158411 · DOI 10.1093/ecco-jcc/jjx003

Verify or expand the search:

Other trials of ABT-494

Trials testing the same drug.

NCT02365649 — A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endosc · Phase 2 · completed

Other recruiting trials for Crohn's Disease (CD)

Currently open trials in the same condition.

NCT07237516 — Zymfentra (Infliximab-dyyb) REal World Cohort STudy · recruiting
NCT04779320 — A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) · Phase 3 · recruiting

Other AbbVie trials

Trials by the same sponsor.

NCT07219017 — A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants · Phase 1 · completed
NCT05316220 — A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years W · Phase 3 · withdrawn
NCT07024797 — Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult · Phase 1 · completed
NCT07058051 — Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China · completed
NCT07007091 — A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02782663 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AbbVie
Last refreshed: 31 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02782663.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing